Janssen Pharms. v. Kennedy
On January 22, 2026, WLF urged the Supreme Court to grant certiorari and invalidate the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. As WLF’s brief explains, that program is not a free and fair “negotiation,” but is a regime that compels speech to effect an unlawful and uncompensated taking, backed by unconstitutional excessive fines. As such, the Program violates the First, Fifth, and Eighth Amendments.